Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

June 3, 2024

https://www.globenewswire.com/news-release/2024/06/03/2892216/0/en/Denali-Therapeutics-Announces-FDA-Has-Selected-DNL126-ETV-SGSH-for-MPS-IIIA-Sanfilippo-Syndrome-Type-A-for-START-Pilot-Program-Intended-to-Accelerate-Development-of-Rare-Disease-Th.html

SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq:DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage diseases, today announced that the U.S. Food and Drug Administration (FDA) has selected DNL126 for participation in the Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program. DNL126 is an investigational enzyme replacement therapy designed to cross the BBB for the potential treatment of MPS IIIA (Sanfilippo syndrome type A).

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.